The estimated Net Worth of Christopher Downs is at least 411 千$ dollars as of 1 February 2024. Mr Downs owns over 66,666 units of Cns Pharmaceuticals Inc stock worth over 16,550$ and over the last 8 years he sold CNSP stock worth over 0$. In addition, he makes 394,700$ as Chief Financial Officer at Cns Pharmaceuticals Inc.
Mr has made over 8 trades of the Cns Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 66,666 units of CNSP stock worth 20,000$ on 1 February 2024.
The largest trade he's ever made was buying 142,000 units of Cns Pharmaceuticals Inc stock on 24 August 2020 worth over 289,680$. On average, Mr trades about 15,099 units every 139 days since 2016. As of 1 February 2024 he still owns at least 103,438 units of Cns Pharmaceuticals Inc stock.
You can see the complete history of Mr Downs stock trades at the bottom of the page.
Christopher S. Downs CPA, CTP, FP&A is the Chief Financial Officer at Cns Pharmaceuticals Inc.
As the Chief Financial Officer of Cns Pharmaceuticals Inc, the total compensation of Mr A at Cns Pharmaceuticals Inc is 394,700$. There are 1 executives at Cns Pharmaceuticals Inc getting paid more, with John Michael Climaco Esq., J.D. having the highest compensation of 635,100$.
Mr A is 42, he's been the Chief Financial Officer of Cns Pharmaceuticals Inc since . There are 3 older and no younger executives at Cns Pharmaceuticals Inc. The oldest executive at Cns Pharmaceuticals Inc is Dr. Donald H. Picker Ph.D., 75, who is the Chief Science Officer.
Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over 132,960$ worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth 458,622$ . The most active insiders traders include Christopher Downs、John M Climaco、Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of 6,051$. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth 10,000$.
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include: